Week 2What can we expect in week 2 of the "post Arbitration" era. Week 1 was surprsingly benign. A little volume from the panickers but after that little volume and the share price flat lined.
What is needed in week 2 is the plan.
How does Replicel move forward ? I imagine Andrew and his Directors have met and discussed what now needs to be done.
For sure it involves accelerating the development and approval of the Dermal Injector. It is the closest asset that can be taken to commercialization and revenue generation. This will have to include financial support from Mainpointe. This will signal to the market that Replicel is still a viable company